Loss of patients in clinical trials that measure long-term survival following myocardial infarction

Controlled Clinical Trials

Volumn 7, Issue 2, 1986, Pages 134-148

  Bhaskar, Rohit ^a   Reitman, Dinah ^a   Sacks, Henry S ^a   Smith Jr , Harry ^a   Chalmers, Thomas C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

clinical trials; myocardial infarction; patient dropouts

Indexed keywords

CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; EPIDEMIOLOGY; HEART; HEART INFARCTION; HUMAN; MONITORING; PRIORITY JOURNAL; SURVIVAL; THEORETICAL STUDY;

CLINICAL TRIALS; HUMANS; MYOCARDIAL INFARCTION; PATIENT DROPOUTS; RANDOM ALLOCATION; STATISTICS; TIME FACTORS;

EID: 0022550075     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-2456(86)90029-2     Document Type: Article

References (21)

1. Terminology—A plea for standardization
2. Controversy in counting and attributing events in clinical trials
3. An additional basic science for clinical medicine: 1. The limitations of randomized trials
4. The qualification and disqualification of patients and events in long term cardiovascular clinical trials
5. The randomised clinical trial: bias in analysis
6. Explanatory and pragmatic attitudes in therapeutical trials
7. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. 1. Introduction and design
8. Extracranial vascular surgery
9. Sulfinpyrazone in the prevention of cardiac death after myocardial infarction The Anturane Reinfarction Trial
10. Presentation and analysis of the results of clinical trials in cardiovascular disease
11. The clinical trial
12. Sulfinpyrazone in the prevention of sudden death after myocardial infarction
13. Streptokinase in recent myocardial infarction: a controlled multicentre trial
14. The FDA's critique of the Anturane Reinfarction Trial
15. Sulfinpyrazone after myocardial infarction: No decision yet
16. Applying results of randomised trials to clinical practice: impact of losses before randomisation
17. Reporting of standards and research strategies for controlled trials. Agenda for the editor
18. A Method for assessing the quality of a randomized control trial
19. Content of reports on clinical trials A critical review
20. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial
21. The use of beta-blockers for the reduction of mortality after myocardial infarction